+

WO2010116385A3 - Pharmaceutical compositions for alleviating unpleasant taste - Google Patents

Pharmaceutical compositions for alleviating unpleasant taste Download PDF

Info

Publication number
WO2010116385A3
WO2010116385A3 PCT/IN2010/000228 IN2010000228W WO2010116385A3 WO 2010116385 A3 WO2010116385 A3 WO 2010116385A3 IN 2010000228 W IN2010000228 W IN 2010000228W WO 2010116385 A3 WO2010116385 A3 WO 2010116385A3
Authority
WO
WIPO (PCT)
Prior art keywords
eszopiclone
taste
pharmaceutical compositions
unpleasant
relates
Prior art date
Application number
PCT/IN2010/000228
Other languages
French (fr)
Other versions
WO2010116385A2 (en
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Original Assignee
Rubicon Research Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Private Limited filed Critical Rubicon Research Private Limited
Publication of WO2010116385A2 publication Critical patent/WO2010116385A2/en
Publication of WO2010116385A3 publication Critical patent/WO2010116385A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to oral pharmaceutical compositions that alleviate the bitter, unpleasant or metallic taste associated with eszopiclone therapy. The invention relates to pharmaceutical compositions comprising eszopiclone, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. This taste-masked eszopiclone formulation that masks the immediate unpleasant or objectionable taste of eszopiclone is provided in dosage forms suitable for oral administration such as orally disintegrating tablets, bite-dispersion tablets, dispersible tablets, or the like. The invention further relates to a method of countering this unpleasant after-taste of eszopiclone comprising administering to the patients in need thereof a composition devoid of the active agent either along with or subsequently at an appropriate time after administration of taste-masked eszopiclone.
PCT/IN2010/000228 2009-04-08 2010-04-08 Pharmaceutical compositions for alleviating unpleasant taste WO2010116385A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN931MU2009 2009-04-08
IN931/MUM/2009 2009-04-08

Publications (2)

Publication Number Publication Date
WO2010116385A2 WO2010116385A2 (en) 2010-10-14
WO2010116385A3 true WO2010116385A3 (en) 2011-01-20

Family

ID=42936653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000228 WO2010116385A2 (en) 2009-04-08 2010-04-08 Pharmaceutical compositions for alleviating unpleasant taste

Country Status (1)

Country Link
WO (1) WO2010116385A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010116385A2 (en) * 2009-04-08 2010-10-14 Rubicon Research Private Limited Pharmaceutical compositions for alleviating unpleasant taste
CN102727452B (en) * 2011-04-01 2014-12-24 成都康弘药业集团股份有限公司 Eszopiclone-containing particle and its preparation method
WO2013038323A1 (en) * 2011-09-13 2013-03-21 Unimark Remedies Ltd. Taste masked pharmaceutical compositions of cefuroxime axetil
AR091349A1 (en) * 2012-04-30 2015-01-28 Otsuka Pharma Co Ltd ORAL FORMULATION
WO2014012571A1 (en) * 2012-07-16 2014-01-23 Ratiopharm Gmbh Complex of agomelatine and cyclodextrin
WO2014148883A1 (en) * 2013-03-20 2014-09-25 Natureceuticals Sdn Bhd Herbaceutical formulations
WO2014184663A2 (en) * 2013-05-15 2014-11-20 Apr Applied Pharma Research Sa Orally dispersible drug formulations
CN104922687A (en) * 2015-04-21 2015-09-23 襄阳市中心医院 Eszopiclone-cyclodextrin inclusion compound and preparation method thereof
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10342886B2 (en) 2016-01-26 2019-07-09 S.C. Johnson & Son, Inc. Extruded wax melt and method of producing same
US10010638B2 (en) 2016-06-14 2018-07-03 S. C. Johnson & Son, Inc. Wax melt with filler
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7304691B2 (en) * 2018-12-06 2023-07-07 日本ケミファ株式会社 Tablets containing Zopiclone, its optical isomers, or salts thereof as active ingredients
CN109925331A (en) * 2019-04-19 2019-06-25 中国农业科学院农产品加工研究所 A kind of peanut stem leaf extract and the preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066984A2 (en) * 2003-01-31 2004-08-12 Glenmark Pharmaceuticals Limited Improved taste masking pharmaceutical composition and process for its preparation
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050222157A1 (en) * 2004-04-05 2005-10-06 Thomas Wessel Methods of treatment of menopause and perimenopause using eszopiclone
US20060159624A1 (en) * 1997-10-01 2006-07-20 Dugger Harry A Iii Buccal, polar and non-polar spray containing zolpidem
WO2007005962A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and an antidepressant
US20070123562A1 (en) * 2005-05-25 2007-05-31 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the-night insomnia
WO2010116385A2 (en) * 2009-04-08 2010-10-14 Rubicon Research Private Limited Pharmaceutical compositions for alleviating unpleasant taste

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206025A (en) 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
FR2671800B1 (en) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa OPTICALLY ACTIVE 5H-PYRROLO [3,4-B] PYRAZINE DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159624A1 (en) * 1997-10-01 2006-07-20 Dugger Harry A Iii Buccal, polar and non-polar spray containing zolpidem
WO2004066984A2 (en) * 2003-01-31 2004-08-12 Glenmark Pharmaceuticals Limited Improved taste masking pharmaceutical composition and process for its preparation
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050222157A1 (en) * 2004-04-05 2005-10-06 Thomas Wessel Methods of treatment of menopause and perimenopause using eszopiclone
US20070123562A1 (en) * 2005-05-25 2007-05-31 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the-night insomnia
WO2007005962A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and an antidepressant
WO2010116385A2 (en) * 2009-04-08 2010-10-14 Rubicon Research Private Limited Pharmaceutical compositions for alleviating unpleasant taste

Also Published As

Publication number Publication date
WO2010116385A2 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2010116385A3 (en) Pharmaceutical compositions for alleviating unpleasant taste
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
WO2012007159A3 (en) Novel gastro-retentive dosage forms
WO2011030351A3 (en) Taste - masked pharmaceutical compositions
WO2010123569A3 (en) Immunonanotherapeutics providing a th1-biased response
WO2013183062A3 (en) Palatable formulations of ibuprofen
JP2012502047A5 (en)
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery
NZ599344A (en) Formulations comprising triptan compounds
NZ597488A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2011041632A3 (en) Combination therapies for the treatment of obesity
UA105644C2 (en) Methods of treating pulmonary disorders with liposomal amikacin formulations
WO2009026473A3 (en) Stabilized therapeutic compositions and formulations
WO2011074015A3 (en) Composition of pharmaceutical product to treat sexual dysfunction
WO2010045417A3 (en) Combination therapies for the treatment of obesity
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
MX2011007779A (en) Galenic formulations of organic compounds.
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
HRP20192189T1 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2010003472A3 (en) Lozenge composition for treating inflammatory diseases of the mouth and pharynx
JP2016505050A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10747682

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10747682

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载